Dyadic to Attend Industry and Investor Events in May
Dyadic to Attend Industry and Investor Events in May
JUPITER, Fla., May 08, 2024 — Dyadic International, Inc. ("Dyadic", or the "Company") (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and to develop and manufacture prophylactic, therapeutic, and nutritional biopharmaceutical products for human and animal health and wellness, today announced that its management will be attending the following industry and investor events during the month of May 2024.
佛羅里達州朱庇特，2024年5月8日——全球生物技術公司Dyadic International, Inc.（“Dyadic” 或 “公司”）（納斯達克股票代碼：DYAI）今天宣佈，其管理層將出席，該公司是一家全球生物技術公司，專注於建立創新微生物平台，以滿足對全球蛋白質生物生產不斷增長的需求，開發和製造用於人類和動物健康的預防、治療和營養生物製藥產品。2024 年 5 月的以下行業和投資者活動。
PEGS Boston
Omni Boston Hotel at The Seaport, Boston, MA
May 13 – 17, 2024
PEGS 波士頓
馬薩諸塞州波士頓海港全方位波士頓酒店
2024 年 5 月 13 日至 17 日
EFHutton Annual Global Conference
The Plaza Hotel, New York City
May 15, 2024
eFutton 年度全球會議
紐約市廣場酒店
2024年5月15日
ECI Vaccine Technology IX
Secrets Puerto Los Cabos Resort Hotel, San José del Cabo, B.C.S., Mexico
May 19 – 24, 2024
Novel Expression Track: "Development of the Thermophilic Filamentous Fungus Thermothelomyces heterothallica C1 into a prominent human and animal vaccines production platform"
ECI 疫苗技術 IX
墨西哥不列顛哥倫比亞省聖何塞德爾卡波的祕密洛斯卡沃斯港度假酒店
2024 年 5 月 19 日至 24 日
Novel Expression Track：“將嗜熱絲狀真菌 Thermothelomyces heterothallica C1 開發成一個傑出的人類和動物疫苗生產平台”
Lytham Spring 2024 Investor Conference
Virtual
May 30, 2024, 11:45AM-12:15PM EST
萊瑟姆2024年春季投資者大會
虛擬
美國東部標準時間 2024 年 5 月 30 日上午 11:45 至下午 12:15
If you would like to schedule a meeting with one of our management members at any of these events, please contact Heidi Zosiak at hzosiak@dyadic.com.
如果您想安排在這些活動中與我們的一位管理層成員會面，請通過以下方式與海蒂·佐西亞克聯繫 hzosiak@dyadic.com。
About Dyadic International, Inc.
關於 Dyadic International,
Dyadic International, Inc. is a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics, as well as in non-pharmaceutical applications including food, nutrition, and wellness.
Dyadic International, Inc. 是一家生物技術公司，專注於高效大規模生產用於人類和動物疫苗和療法以及食品、營養和健康等非藥物應用的蛋白質。
Dyadic's gene expression and protein production platforms are based on the highly productive and scalable fungus Thermothelomyces heterothallica (formerly Myceliophthora thermophila). Our lead technology, C1-cell protein production platform, is based on an industrially proven microorganism (named C1), which is currently used to speed development, lower production costs, and improve performance of biologic vaccines and drugs at flexible commercial scales for the human and animal health markets. Dyadic has also developed the Dapibus filamentous fungal based microbial protein production platform to enable the rapid development and large-scale manufacture of low-cost proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, such as food, nutrition, and wellness.
Dyadic 的基因表達和蛋白質生產平台基於高產量和可擴展的真菌 Thermothelomyces heterot （以前是 myceliophthora thermophila）。 我們的領先技術——C1細胞蛋白生產平台基於一種經過工業驗證的微生物（名爲C1），該微生物目前用於加快開發、降低生產成本並以靈活的商業規模改善人類和動物健康市場的生物疫苗和藥物的性能。Dyadic還開發了基於Dapibus絲狀真菌的微生物蛋白生產平台，以實現低成本蛋白質、代謝物和其他生物產品的快速開發和大規模生產，用於食品、營養和保健等非藥物應用。
With a passion to enable our partners and collaborators to develop effective preventative and therapeutic treatments in both developed and emerging countries, Dyadic is building an active pipeline by advancing its proprietary microbial platform technologies, including our lead asset DYAI-100 COVID-19 vaccine candidate, as well as other biologic vaccines, antibodies, and other biological products.
Dyadic 熱衷於幫助我們的合作伙伴和合作者在發達國家和新興國家開發有效的預防和治療方法，正在通過推進其專有微生物平台技術（包括我們的主要資產 DYAI-100 COVID-19 候選疫苗）以及其他生物疫苗、抗體和其他生物製品，來建立一個活躍的產品線。
To learn more about Dyadic and our commitment to helping bring vaccines and other biologic products to market faster, in greater volumes and at lower cost, please visit https://www.dyadic.com.
要了解有關Dyadic以及我們致力於幫助更快、更大批量和更低成本將疫苗和其他生物產品推向市場的承諾，請訪問 https://www.dyadic.com。
Safe Harbor Regarding Forward-Looking Statements
關於前瞻性陳述的安全港
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including those regarding Dyadic International's expectations, intentions, strategies, and beliefs pertaining to future events or future financial performance, such as the issuance of Convertible Notes and the use of proceeds thereof. Actual events or results may differ materially from those in the forward-looking statements because of various important factors, including those described in the Company's most recent filings with the SEC. Dyadic assumes no obligation to update publicly any such forward-looking statements, whether because of new information, future events or otherwise. For a more complete description of the risks that could cause our actual results to differ from our current expectations, please see the section entitled "Risk Factors" in Dyadic's annual reports on Form 10-K and quarterly reports on Form 10-Q filed with the SEC, as such factors may be updated from time to time in Dyadic's periodic filings with the SEC, which are accessible on the SEC's website and at www.dyadic.com.
本新聞稿包含1933年《證券法》第27A條和1934年《證券交易法》第21E條所指的前瞻性陳述，包括與Dyadic International與未來事件或未來財務業績（例如可轉換票據的發行及其收益的使用）有關的預期、意圖、戰略和信念的陳述。由於各種重要因素，包括公司最近向美國證券交易委員會提交的文件中描述的因素，實際事件或結果可能與前瞻性陳述中的事件或結果存在重大差異。無論是由於新信息、未來事件還是其他原因，Dyadic都沒有義務公開更新任何此類前瞻性陳述。要更完整地描述可能導致我們的實際業績與當前預期不同的風險，請參閱Dyadic向美國證券交易委員會提交的10-K表年度報告和10-Q表季度報告中標題爲 “風險因素” 的部分，因爲這些因素可能會在Dyadic向美國證券交易委員會提交的定期文件中不時更新，這些文件可在美國證券交易委員會的網站和上網查閱 www.dyadic.com。
Contact:
Dyadic International, Inc.
Ping W. Rawson
Chief Financial Officer
Phone: (561) 743-8333
Email: ir@dyadic.com
聯繫人：
Dyadic International
Ping W. Rawson
首席財務官
電話：(561) 743-8333
電子郵件： ir@dyadic.com
譯文內容由第三人軟體翻譯。